MIRA Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About MIRA Interactive Breakdown Better Bets vs. MIRA Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Mira Pharmaceuticals (MIRA)

    Market Price (9/21/2026): $0.8051 | Market Cap: $33.8 MilSector: Health Care | Industry: Pharmaceuticals

    Mira Pharmaceuticals (MIRA)

    Market Price (9/21/2026): $0.8051
    Market Cap: $33.8 Mil
    Sector: Health Care
    Industry: Pharmaceuticals

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -74%, 3Y Excs Rtn is -151%

    Penny stock
    Mkt Price is 0.8

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -9.4 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31%

    Key risks
    MIRA key risks include [1] substantial doubt about its ability to continue as a going concern, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -74%, 3Y Excs Rtn is -151%
    3 Penny stock
    Mkt Price is 0.8
    4 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    5 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -9.4 Mil
    6 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31%
    7 Key risks
    MIRA key risks include [1] substantial doubt about its ability to continue as a going concern, Show more.

    MIRA in ETFs

    Weight = MIRA's share of each fund

    VTI0.00%

    Valuation & Metrics

    FYE: 12/31MIRA [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$276.0 Mil—
    FY 2027 Sales$40.0 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth-85.5%12.9%
    EARNINGS
    LTM Net Income (GAAP) [3]$-9.5 Mil—
    FY 2026 Net Income (Non-GAAP)$-2.8 Mil—
    FY 2027 Net Income (Non-GAAP)$-3.8 Mil—
    FY 2027 Net Income Growth—18.1%
    FY 2026 EPS (Non-GAAP)$-0.12—
    FY 2027 EPS (Non-GAAP)$-0.16—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S0.11.6
    FY 2027 P/S0.8—
    FY 2026 P/E—7.4
    FY 2027 P/E——

    [1] MIRA forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Drug Candidates in Pipeline39302025Link
    Ketamir-2 Clinical Trial PhasePhase 1 Multiple Ascending Dose (MAD) study initiated10242025Link
    MIRA-55 Development PhasePre-clinical10242025Link
    Number of Participants in Ketamir-2 Phase 1 SAD study329222025Link
    Number of recent acquisitions19302025Link
    Number of patent applications filed19102025Link

    Price Chart

    null
    Upcoming
    12/02/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/18/2026

    Mira Pharmaceuticals (MIRA) stock has lost about 20% since 5/31/2026 because of the following key factors:

    1. Significant Shareholder Dilution.

    Mira Pharmaceuticals experienced substantial dilution, with total shares outstanding increasing by 120.4% over the past year. This dilution directly reduces the value of existing shares and can lead to downward pressure on the stock price.

    2. Continued Unprofitability and Weak Analyst Sentiment.

    The company reported an Earnings Per Share (EPS) of -$0.03 for fiscal Q2 2026, highlighting ongoing unprofitability common for clinical-stage biopharmaceutical companies. This financial position contributes to a "Hold" consensus rating from analysts, with Mira Pharmaceuticals scoring lower than its healthcare sector peers (2.00 vs. 2.30 average rating score) and ranking in the bottom 20% of healthcare stocks by MarketBeat's MarketRank™, reflecting thin or unreliable profits and potential challenges in financial health and growth prospects.

    Show more
    Updated on 9/18/2026

    Mira Pharmaceuticals (MIRA) stock has lost about 20% since 5/31/2026 because of the following key factors:

    1. Significant Shareholder Dilution.

    Mira Pharmaceuticals experienced substantial dilution, with total shares outstanding increasing by 120.4% over the past year. This dilution directly reduces the value of existing shares and can lead to downward pressure on the stock price.

    2. Continued Unprofitability and Weak Analyst Sentiment.

    The company reported an Earnings Per Share (EPS) of -$0.03 for fiscal Q2 2026, highlighting ongoing unprofitability common for clinical-stage biopharmaceutical companies. This financial position contributes to a "Hold" consensus rating from analysts, with Mira Pharmaceuticals scoring lower than its healthcare sector peers (2.00 vs. 2.30 average rating score) and ranking in the bottom 20% of healthcare stocks by MarketBeat's MarketRank™, reflecting thin or unreliable profits and potential challenges in financial health and growth prospects.

    3. Early-Stage Pipeline with Distant Catalysts.

    Despite positive updates on its pipeline, including advancing Ketamir-2 to Phase 2a clinical studies targeting site initiation in fiscal Q1 2027 for chemotherapy-induced peripheral neuropathy (CIPN), and progressing MIRA-55 and SKNY-1 toward Investigational New Drug (IND) enabling studies with an IND submission target for MIRA-55 also in fiscal Q1 2027, these are long-term development timelines. The absence of significant near-term clinical milestones or commercialization prospects may have led to investor impatience and profit-taking in the period.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -21.5% change in MIRA stock from 5/31/2026 to 9/20/2026 was primarily driven by a -0.2% change in the company's Shares Outstanding (Mil).
    (LTM values as of)53120269202026Change
    Stock Price ($)1.060.83-21.5%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)4242-0.2%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/20/2026
    ReturnCorrelation
    MIRA-21.5% 
    Market (SPY)0.9%-11.3%
    Sector (XLV)12.7%12.6%

    Fundamental Drivers

    The -34.5% change in MIRA stock from 2/28/2026 to 9/20/2026 was primarily driven by a -54.1% change in the company's Shares Outstanding (Mil).
    (LTM values as of)22820269202026Change
    Stock Price ($)1.270.83-34.5%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1942-54.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/20/2026
    ReturnCorrelation
    MIRA-34.5% 
    Market (SPY)11.6%13.7%
    Sector (XLV)5.5%17.8%

    Fundamental Drivers

    The -39.2% change in MIRA stock from 8/31/2025 to 9/20/2026 was primarily driven by a -59.6% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120259202026Change
    Stock Price ($)1.370.83-39.2%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1742-59.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/20/2026
    ReturnCorrelation
    MIRA-39.2% 
    Market (SPY)19.4%14.1%
    Sector (XLV)24.1%12.3%

    Fundamental Drivers

    The -86.7% change in MIRA stock from 8/31/2023 to 9/20/2026 was primarily driven by a -64.9% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120239202026Change
    Stock Price ($)6.270.83-86.7%
    Change Contribution By: 
    Total Revenues ($ Mil)�00.0%
    P/S Multiple�∞0.0%
    Shares Outstanding (Mil)1542-64.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/20/2026
    ReturnCorrelation
    MIRA-86.7% 
    Market (SPY)75.6%5.8%
    Sector (XLV)32.3%4.5%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    MIRA Return---86%9%32%-50%-90%
    Peers Return-36%4%-8%-17%239%27%121%
    S&P 500 Return27%-19%24%23%16%12%103%

    Monthly Win Rates [3]
    MIRA Win Rate--20%33%50%22% 
    Peers Win Rate43%57%43%48%67%47% 
    S&P 500 Win Rate75%42%67%75%67%44% 

    Max Drawdowns [4]
    MIRA Max Drawdown----80%-46%-59% 
    Peers Max Drawdown-50%-53%-41%-48%-44%-24% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: AXSM, JAZZ, ATAI, NBIX, RLMD.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/18/2026 (YTD)

    How Low Can It Go

    EventMIRAS&P 500
    2025 US Tariff Shock
      % Loss-30.8%-18.8%
      % Gain to Breakeven44.5%23.1%
      Time to Breakeven23 days79 days

    Compare to AXSM, JAZZ, ATAI, NBIX, RLMD

    In The Past

    Mira Pharmaceuticals's stock fell -30.8% during the 2025 US Tariff Shock. Such a loss loss requires a 44.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventMIRAS&P 500
    2025 US Tariff Shock
      % Loss-30.8%-18.8%
      % Gain to Breakeven44.5%23.1%
      Time to Breakeven23 days79 days

    Compare to AXSM, JAZZ, ATAI, NBIX, RLMD

    In The Past

    Mira Pharmaceuticals's stock fell -30.8% during the 2025 US Tariff Shock. Such a loss loss requires a 44.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Mira Pharmaceuticals (MIRA)

    Mira Pharmaceuticals (MIRA) is an early pre-clinical-stage pharmaceutical company dedicated to developing and commercializing a novel drug candidate named MIRA1a. This drug is a new molecular synthetic THC analog specifically designed to address a range of conditions in adult patients, including anxiety, cognitive decline typically associated with early-stage dementia, and chronic pain.

    MIRA1a's mechanism of action involves selectively targeting cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. Based on pre-clinical studies, Mira Pharmaceuticals believes MIRA1a can enhance therapeutic potential by striking a balance between the beneficial effects of THC and CBD. It aims to achieve this by potentially having less potency at CB1 (which correlates with intoxication) while maintaining strong activation at CB2, thereby reducing intoxicating side effects and potentially unmasking positive effects like cognitive performance enhancement. The company envisions MIRA1a as a significant advancement for treating various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

    AI Analysis | Feedback

    Here are 1-2 brief analogies for Mira Pharmaceuticals:

    • The Jazz Pharmaceuticals (formerly GW Pharmaceuticals) of next-generation synthetic cannabinoid drugs.

    • An early-stage Eli Lilly focused on developing novel synthetic cannabinoid drugs for cognitive decline and pain.

    AI Analysis | Feedback

    • MIRA1a: An investigational synthetic THC analog being developed for the treatment of anxiety, cognitive decline associated with early-stage dementia, and chronic pain.

    AI Analysis | Feedback

    ```html

    Mira Pharmaceuticals (MIRA) is an early pre-clinical-stage pharmaceutical company. At this stage, the company is focused on the research and development of its drug candidate, MIRA1a, and has not yet undergone clinical trials or received FDA approval for commercialization.

    Therefore, Mira Pharmaceuticals does not currently have any major customers for its drug products, as it is not yet selling MIRA1a to other companies or directly to individuals.

    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Erez Aminov, Chairman of the Board and Chief Executive Officer

    Erez Aminov was appointed Chief Executive Officer in April 2023. He brings deep expertise in biotechnology consulting, investment, and leadership. Prior to joining MIRA Pharmaceuticals, he founded Locate Venture Corp, where he supported early-stage biotech enterprises and fostered growth through strategic partnerships. He has also served as a trusted consultant for multiple biotech firms and successfully guided two companies through IPOs on the Nasdaq. Additionally, he serves as the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc..

    Alan Weichselbaum, Chief Financial Officer

    Alan Weichselbaum was appointed Chief Financial Officer effective May 15, 2025. He has over 30 years of experience in corporate finance, capital markets, and strategic advisory. He currently serves as CFO of both MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc. Since 2015, he has been a Director of FinWise Bancorp. In 2011, Mr. Weichselbaum founded The Wexus Group, an outsourced CFO advisory firm. From 1995 to 2010, he held senior roles on Wall Street, including equity analyst, manager of two hedge funds, and CEO of a boutique brokerage firm. His career also includes managerial positions at Philip Morris Capital Corporation and Price Waterhouse.

    Adam Kaplin, Co-Founder, President & Chief Science Officer

    Dr. Adam Kaplin co-founded MIRA Pharmaceuticals, Inc. in 2020. He is a neuropsychiatrist specializing in the biological basis of immune-mediated depression and cognitive impairment. Previously, he served as the chief neuropsychiatric consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence and was the founder and director of the Johns Hopkins Ketamine Clinic. He has also co-founded other healthcare-related startups, including REWARD Pathways, focused on addiction treatment.

    Itzchak Angel, Chief Scientific Advisor

    Dr. Itzchak Angel is an accomplished executive with over 40 years of experience in the pharmaceutical industry, guiding medical, pharmaceutical, drug, and business development. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.), assisting various companies in drug development. He previously served as Head of Pharmacology at Synthelabo (now Sanofi-Aventis), where he contributed to the research and development of drugs such as Xatral, Ambien, and Mizollen.

    Ned MacPherson, Director

    Ned MacPherson currently serves as Chief Growth Officer for Power Digital. From May 2016 to December 2023, he was the CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and subsequently sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at companies including sunglass maker Prive Revaux, curated meal company Menud, and Rejuvenetics, LLC.

    AI Analysis | Feedback

    ```html

    The primary key risk to Mira Pharmaceuticals is the inherent uncertainty and extensive process of developing its sole drug candidate, MIRA1a, from an early pre-clinical stage through clinical trials to gain regulatory approval. The company's future success is entirely dependent on the successful development, FDA approval, and commercialization of MIRA1a, which faces significant hurdles given that current data is based on pre-clinical and animal studies and does not guarantee success in human trials or eventual market approval.

    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Mira Pharmaceuticals (MIRA) is developing MIRA1a for the treatment of anxiety, cognitive decline typically associated with early-stage dementia, and chronic pain. The addressable markets for these indications are substantial:

    • Anxiety Treatment Market: The global anxiety disorders treatment market is estimated to be approximately USD 11.59 billion in 2024, with projections indicating growth to around USD 15.90 billion by 2032. Another estimate places the global anxiety disorders treatment market at USD 12.33 billion in 2025, expected to reach USD 17.56 billion by 2035. North America held a significant share of the global market in 2025.
    • Cognitive Decline (Early-Stage Dementia) Treatment Market: The global dementia treatment market was estimated at USD 18.03 billion in 2024 and is projected to reach USD 28.11 billion by 2030. Similarly, the global dementia treatment market size was valued at USD 19.98 billion in 2025 and is expected to reach USD 38.37 billion by 2033. The U.S. dementia treatment market alone was approximately USD 6,261.6 million in 2024 and is expected to grow to USD 9,290.6 million by 2030. North America consistently holds a significant share of the global market.
    • Chronic Pain Treatment Market: The global chronic pain treatment market was valued at approximately USD 84.23 billion in 2024 and is expected to reach USD 132.08 billion by 2030. Other estimates suggest the global market was around USD 90.73 billion in 2024 and is anticipated to reach USD 152.42 billion by 2032. North America represents a significant portion of this market, with one report indicating it held approximately 45% market share in 2024. The U.S. chronic pain management market was valued at USD 31.18 billion in 2025 and is projected to reach USD 42.87 billion by 2034.

    AI Analysis | Feedback

    Mira Pharmaceuticals (MIRA) is an early clinical-stage pharmaceutical company, and as such, it currently generates no revenue from product sales. Its future revenue growth over the next 2-3 years will primarily be driven by key developmental and strategic milestones for its drug candidates, rather than immediate product sales. Analysts generally lack sufficient data to forecast traditional revenue growth for the company at this stage. The expected drivers of future revenue growth for Mira Pharmaceuticals over the next 2-3 years include: * Progression of Ketamir-2 through clinical trials: Ketamir-2, an oral ketamine analog, has successfully completed the Single Ascending Dose (SAD) portion of its Phase 1 clinical trial and is currently advancing into the Multiple Ascending Dose (MAD) stage. The company has also identified chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for a planned Phase 2a clinical evaluation, with an intent to submit the protocol by year-end 2025. Successful advancement through these clinical trial phases would significantly de-risk the asset, enhance its valuation, and pave the way for potential commercialization or partnerships, thereby driving future revenue. * Advancement of MIRA-55 into clinical trials: MIRA-55 (formerly MIRA1a), a synthetic THC analog, is in preclinical development for treating anxiety, cognitive decline, and chronic pain. A critical driver of future revenue potential will be the successful completion of preclinical studies and the filing of an Investigational New Drug (IND) application with the FDA, leading to the initiation of Phase 1 human clinical trials. Notably, the U.S. Drug Enforcement Administration (DEA) has determined that MIRA-55 is not a controlled substance, which could streamline its development and market access. * Formation of strategic partnerships and licensing agreements: Given the substantial capital and resources required for drug development, securing strategic partnerships or licensing agreements for either Ketamir-2 or MIRA-55 would be a significant revenue driver. Such agreements could provide upfront payments, milestone payments tied to development progress, and future royalties, offering non-dilutive funding and leveraging the development and commercialization expertise of larger pharmaceutical companies.

    AI Analysis | Feedback

    Share Issuance

    • Mira Pharmaceuticals completed an initial public offering (IPO) in August 2023, pricing 1,275,000 shares of common stock at $7.00 per share, which generated aggregate gross proceeds of $8.9 million.
    • In October 2025, the company raised approximately $3,835,485 in gross proceeds by selling 1,751,000 shares of common stock through at-the-market (ATM) block sales to institutional investors at an average price of $2.19 per share.
    • The company also financed operations through a private placement of common stock during the fourth quarter of 2021 and throughout 2022.

    Inbound Investments

    • As part of the acquisition of SKNY Pharmaceuticals in September 2025, SKNY contributed $5 million in marketable securities to Mira Pharmaceuticals, which strengthened MIRA's balance sheet.
    • Institutional investors purchased a total of 382,371 shares of MIRA Pharmaceuticals' stock over the two years leading up to February 2026, representing approximately $502.42K in transactions.

    Outbound Investments

    • Mira Pharmaceuticals completed the acquisition of 100% of SKNY Pharmaceuticals, Inc. in September 2025, in an all-stock transaction. This acquisition expanded MIRA's pipeline to include therapeutic programs such as SKNY-1 for obesity and smoking cessation.

    Capital Expenditures

    • Information from financial statements, including cash flow statements, indicates that capital expenditures have been consistently reported as "N/A". This is typical for an early-stage biopharmaceutical company primarily focused on research and development activities.

    Peer Outperformance in Pharmaceuticals

    null
    Share of Pharmaceuticals constituents that MIRA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    32%
    of 73 industry peers · -33.4% return
    3Y
    21%
    of 68 industry peers · -81.5% return
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Pharmaceuticals is MIRA's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 16.2%43.2%90.1% CAH 392% · MCK 346% · COR 168%
    Managed Health Care 8 40.4%-5.3%2.3% OSCR 84% · HQY 56% · ELV 17%
    Health Care Services 20 21.1%37.6%-0.3% HIMS 239% · RDNT 173% · DGX 76%
    Health Care Facilities 24 6.0%6.5%-4.5% NHC 271% · THC 261% · ENSG 129%
    Health Care Equipment 50 -2.7%-0.2%-21.1% POCI 11050% · UFPT 341% · GKOS 222%
    Pharmaceuticals ← 62 -10.5%14.8%-38.6% LQDA 2472% · INDV 1099% · ETON 1051%
    Health Care Supplies 12 14.1%-8.9%-39.7% LNTH 287% · HAE 54% · MMSI 20%
    Life Sciences Tools & Services 109 4.3%-11.3%-68.4% SNWV 1757% · MEDP 231% · NTRA 199%
    Health Care Technology 21 -25.8%-52.6%-79.2% SPOK 68% · HSTM 3% · VEEV -13%
    Biotechnology 364 0.6%-21.7%-79.4% CELZ 1280% · DNTH 1221% · ELVN 1069%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    SDGRSchrodinger2.252.6%62.3%
    PSPershing Square19.932.3%106.6%
    BBNXBeta Bionics1.032.1%-28.2%
    TEMTempus AI14.031.9%31.8%
    SECZSecuritize1.631.3%-11.7%
    TWSTTwist Bioscience10.431.3%426.5%
    EMATEvolution Metals & Technologies2.530.5%-81.1%
    GEMIGemini Space Station0.730.3%-41.4%
    RUMRumble2.626.8%43.8%
    ALMRAlamar Biosciences2.025.0%58.4%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ADBTAdvasa0.1-47.1%-98.0%
    SWMRSwarmer0.4-39.4%-22.6%
    ALHCAlignment Healthcare1.7-33.8%-57.7%
    XENEXenon Pharmaceuticals4.0-32.2%-11.3%
    FLNCFluence Energy1.0-26.3%-63.0%
    ENVAEnova International4.3-21.8%11.1%
    VYXNCR Voyix0.9-21.2%-33.9%
    ARWRArrowhead Pharmaceuticals9.5-19.8%0.1%
    DMRADamora Therapeutics1.4-19.6%-1.8%
    IONSIonis Pharmaceuticals7.4-18.0%-43.8%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SECZSecuritize1.680.1%-11.7%
    FWDIForward Industries0.755.9%16.5%
    PURRHyperliquid Strategies1.750.1%295.8%
    GEMIGemini Space Station0.747.8%-41.4%
    MSTRStrategy54.347.6%1.3%
    SMTCSemtech17.247.6%151.1%
    CVICVR Energy5.446.3%112.4%
    SDGRSchrodinger2.246.2%62.3%
    EMATEvolution Metals & Technologies2.541.1%-81.1%
    ACVAACV Auctions1.840.3%30.7%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.0-67.6%-20.4%
    IESCIES12.8-47.5%-17.2%
    SWMRSwarmer0.4-46.9%-22.6%
    RAREUltragenyx Pharmaceutical1.5-44.7%-36.9%
    TTANServiceTitan5.2-42.1%-48.3%
    FLNCFluence Energy1.0-39.4%-63.0%
    KRMNKarman4.7-38.6%-51.1%
    XENEXenon Pharmaceuticals4.0-36.2%-11.3%
    DYNDyne Therapeutics2.8-36.1%-12.5%
    DKSDick's Sporting Goods10.7-36.1%-37.5%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    MIRAAXSMJAZZATAINBIXRLMDMedian
    NameMira Pha.Axsome T.Jazz Pha.AtaiBeck.Neurocri.Relmada . 
    Mkt Price0.83207.78240.74-146.234.12146.23
    Mkt Cap0.010.815.2-14.80.510.8
    Rev LTM07774,601-3,3740777
    Op Inc LTM-9-1831,016-806-65-9
    FCF LTM-5-721,311-868-46-5
    FCF 3Y Avg-5-1201,189-630-48-5
    CFO LTM-5-711,661-898-46-5
    CFO 3Y Avg-5-1201,350-665-48-5

    Growth & Margins

    MIRAAXSMJAZZATAINBIXRLMDMedian
    NameMira Pha.Axsome T.Jazz Pha.AtaiBeck.Neurocri.Relmada . 
    Rev Chg LTM-56.9%12.6%-34.4%-34.4%
    Rev Chg 3Y Avg-62.1%7.0%-26.5%-26.5%
    Rev Chg Q-45.5%15.5%-39.5%-39.5%
    QoQ Delta Rev Chg LTM-9.6%3.7%-8.8%-8.8%
    Op Inc Chg LTM-19.4%12.2%65.5%-61.5%7.6%12.2%
    Op Inc Chg 3Y Avg-26.1%-9.1%25.3%-46.0%20.3%20.3%
    Op Mgn LTM--23.5%22.1%-23.9%-22.1%
    Op Mgn 3Y Avg--51.8%17.4%-23.2%-17.4%
    QoQ Delta Op Mgn LTM-1.4%1.6%--1.9%-1.4%
    CFO/Rev LTM--9.2%36.1%-26.6%-26.6%
    CFO/Rev 3Y Avg--30.3%31.9%-24.7%-24.7%
    FCF/Rev LTM--9.3%28.5%-25.7%-25.7%
    FCF/Rev 3Y Avg--30.5%28.3%-23.4%-23.4%

    Valuation

    MIRAAXSMJAZZATAINBIXRLMDMedian
    NameMira Pha.Axsome T.Jazz Pha.AtaiBeck.Neurocri.Relmada . 
    Mkt Cap0.010.815.2-14.80.510.8
    P/S-13.93.3-4.4-4.4
    P/Op Inc-3.7-58.915.0-18.3-7.1-3.7
    P/EBIT-3.7-57.816.9-18.0-7.1-3.7
    P/E-3.7-56.216.2-20.9-7.5-3.7
    P/CFO-7.5-151.09.2-16.4-10.1-7.5
    Total Yield-27.2%-1.8%6.2%-4.8%-13.4%-1.8%
    Dividend Yield0.0%0.0%0.0%-0.0%0.0%0.0%
    FCF Yield 3Y Avg-30.4%-2.4%14.3%-4.3%-103.2%-2.4%
    D/E0.00.00.3-0.00.00.0
    Net D/E-0.2-0.00.1-0.0-0.5-0.0

    Returns

    MIRAAXSMJAZZATAINBIXRLMDMedian
    NameMira Pha.Axsome T.Jazz Pha.AtaiBeck.Neurocri.Relmada . 
    1M Rtn9.0%0.0%-5.3%--4.2%-11.0%-4.2%
    3M Rtn-12.6%-17.1%7.2%--7.6%-38.8%-12.6%
    6M Rtn-9.5%32.4%33.3%-14.5%-32.1%14.5%
    12M Rtn-33.4%79.2%87.6%-0.7%169.3%79.2%
    3Y Rtn-81.5%178.0%81.4%-29.3%43.6%43.6%
    1M Excs Rtn8.8%-4.0%-3.8%--5.2%-14.0%-4.0%
    3M Excs Rtn-14.6%-19.1%5.2%--9.6%-40.8%-14.6%
    6M Excs Rtn-34.2%15.0%16.6%--3.1%-49.9%-3.1%
    12M Excs Rtn-51.4%62.3%69.9%--13.5%156.9%62.3%
    3Y Excs Rtn-151.4%98.7%8.2%--43.3%-47.5%-43.3%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/12/20265/14/20263/31/202611/13/20258/14/20255/14/20253/28/202511/12/20248/13/20245/13/20244/1/202411/13/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-1-1-6-1-2-2-2-2-2-2-3-3
    Operating Income-1-1-6-1-2-2-2-2-2-2-3-3
    Net Income-1-1-6-1-2-2-2-2-2-2-6-4
    EPS-0.03-0.03-0.14-1.18-0.09-0.11-0.15-0.14-0.11-0.15-0.40-0.26
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-9-10-10-7-8-8-8-9-10-9-9-7
    Operating Income TTM-9-10-10-7-8-8-8-9-10-9-9-7
    Net Income TTM-9-10-10-7-8-8-8-11-13-12-12-8
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth25.2%38.9%-138.9%36.7%10.7%-2.1%20.2%34.1%-78.4%-32.0%-126.8%-74.7%
    Operating Income Growth25.2%38.9%-138.9%36.7%10.7%-2.1%20.2%34.1%-78.4%-32.0%-126.8%-74.7%
    Net Income Growth21.4%35.5%-149.3%44.3%9.1%-3.8%58.5%43.0%-33.6%-28.1%-328.9%-98.1%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash8911811343456
    Total Debt000000000000
    Net Debt / (Cash)-8-9-11-8-1-1-3-4-3-4-5-6
    Cash Flows Quarterly            
    FCF from Operations-1-1-1-1-1-2-2-2-1-1-1-2
    Cash Flows TTM            
    FCF from Operations TTM-5-4-5-5-6-6-6-5-5-5-5-4
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-11.0%-10.9%-59.8%-15.7%-19.1%-23.3%-34.2%-31.8%-28.7%-31.3%-58.0%-70.8%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-22.4%-24.1%-26.9%-21.1%-24.4%-26.0%-28.1%-33.0%-40.3%-39.6%-40.5%-38.2%

    Segment Financials

    Revenue by Segment
    $ Mil20252024202320222021
    Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric00000
    Total00000


    Operating Income by Segment
    $ Mil202520242023
    Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric-10-8-9
    Total-10-8-9


    Net Income by Segment
    $ Mil202520242023
    Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric-10-8-12
    Total-10-8-12


    Assets by Segment
    $ Mil202320222021
    Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric513
    Total513


    Price Behavior

    Price Behavior
    Market Price$0.83 
    Market Cap ($ Bil)0.0 
    First Trading Date08/03/2023 
    Distance from 52W High-53.8% 
       50 Days200 Days
    DMA Price$0.80$1.08
    DMA Trenddowndown
    Distance from DMA4.0%-23.2%
     3M1YR
    Volatility84.7%79.2%
    Downside Capture-117.9168.54
    Upside Capture-174.848.94
    Correlation (SPY)-17.3%14.1%
    MIRA Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta0.13-0.08-0.341.061.021.48
    Up Beta-1.32-0.62-1.291.271.291.13
    Down Beta11.861.320.782.331.490.55
    Up Capture-77%-100%-98%-7%23%77%
    Bmk +ve Days10213268138427
    Stock +ve Days13222953109304
    Down Capture-67%60%30%119%116%112%
    Bmk -ve Days11213259113324
    Stock -ve Days8203468128415

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MIRA
    MIRA-35.6%79.0%-0.23-
    Sector ETF (XLV)24.4%16.1%1.1610.5%
    Equity (SPY)16.9%12.9%0.9413.8%
    Gold (GLD)19.1%29.3%0.6012.1%
    Commodities (DBC)46.3%20.6%1.73-4.4%
    Real Estate (VNQ)4.9%13.6%0.1010.4%
    Bitcoin (BTCUSD)-30.6%44.3%-0.7013.5%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MIRA
    MIRA-34.5%378.0%0.37-
    Sector ETF (XLV)6.4%15.2%0.244.5%
    Equity (SPY)12.9%17.2%0.575.7%
    Gold (GLD)19.1%18.8%0.831.5%
    Commodities (DBC)11.2%19.5%0.451.0%
    Real Estate (VNQ)1.1%18.8%-0.055.9%
    Bitcoin (BTCUSD)12.5%52.5%0.424.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MIRA
    MIRA-19.0%378.0%0.37-
    Sector ETF (XLV)10.6%16.7%0.514.5%
    Equity (SPY)15.1%18.0%0.725.7%
    Gold (GLD)12.1%16.4%0.611.5%
    Commodities (DBC)8.3%18.1%0.371.0%
    Real Estate (VNQ)4.4%20.7%0.185.9%
    Bitcoin (BTCUSD)62.6%66.2%1.024.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8312026
    Short Interest: Shares Quantity0.2 Mil
    Short Interest: % Change Since 8152026-2.7%
    Average Daily Volume0.0 Mil
    Days-to-Cover Short Interest4.1 days
    Basic Shares Quantity42.0 Mil
    Short % of Basic Shares0.5%

    Earnings Returns History

    Updated 6/2/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    SUMMARY STATS   
    # Positive000
    # Negative000
    Median Positive   
    Median Negative   
    Max Positive   
    Max Negative   
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    SUMMARY STATS   
    # Positive000
    # Negative000
    Median Positive   
    Median Negative   
    Max Positive   
    Max Negative   

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/14/202610-Q
    12/31/202503/31/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/28/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/13/202410-Q
    03/31/202405/13/202410-Q
    12/31/202304/01/202410-K
    09/30/202311/13/202310-Q
    06/30/202309/15/202310-Q
    03/31/202308/04/2023424B4
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/14/202610-Q
    12/31/202503/31/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/28/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/13/202410-Q
    03/31/202405/13/202410-Q
    12/31/202304/01/202410-K
    09/30/202311/13/202310-Q
    06/30/202309/15/202310-Q
    03/31/202308/04/2023424B4

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/20/2026